A221805 Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II To Phase III Study
Posted Date: Aug 3, 2021
- Investigator: Jordan Kharofa
- Specialties: Cancer, Colorectal Cancer, Oncology
- Type of Study: Drug
This phase II/III trial will study the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Efficacy will be measured by Prevention of sensory oxaliplatin-induced peripheral neuropathy (OIPN) response (Phase II), Prevention of sensory oxaliplatin-induced peripheral neuropathy (OIPN) response (Phase III), and Chronic neuropathic pain response (Phase III).
Criteria:
Eastern Cooperative Oncology Group (Ecog) Performance Status 0-2. Calculated Creatinine Clearance > 30 Ml/Min. Aspartate Aminotransferases (Ast)/Serum Glutamic-Oxaloacetic Transaminase (Sgot) =< 3 X Upper Limit Of Normal (Uln). No Prior Neurotoxic Chemoth
Keywords:
Colorectal, Neuropathy
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com